

Antimicrobial Susceptibility and Distribution of TEM and CTX-M Genes among ESBL-producing *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* Causing Urinary Tract Infections

Saeide Saeidi,¹ Roya Alavi-Naini,^{*2} Sara Shayan³

1. Department of Biology, Faculty of Sciences, Islamic Azad University, Kerman, Iran
2. Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
3. Department of Microbiology, Faculty of Medicine Sciences, Zahedan University of Medical Sciences, Zahedan, Iran

Article information	Abstract
<p>Article history: Received: 15 Feb 2013 Accepted: 17 Apr 2013 Available online: 15 May 2013 ZJRMS 2014; 16(4): 1-5</p> <p>Keywords: <i>Klebsiella pneumoniae</i> <i>Pseudomonas aeruginosa</i> Extended spectrum beta-lactamase TEM gene CTX-M gene PCR</p> <p>*Corresponding author at: Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, Iran. E-mail: ranaini@gmail.com</p>	<p>Background: Extended spectrum beta lactamases (ESBLs) have been observed in nearly all the species of family <i>Enterobacteriaceae</i>. The enzymes are plasmid mediated and are derived from broad-spectrum beta lactamase TEM and CTX- M by a limited number of mutations. This study was undertaken to characterize ESBL producers among <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> by PCR, which were initially screened by phenotypic method.</p> <p>Materials and Methods: A cross-sectional study was performed to evaluate 180 strains (30 <i>K. pneumoniae</i> and 150 <i>P. aeruginosa</i>) isolated from urine culture of hospitalized patients (Amir Al-Momenin Hospital, Zabol, south-eastern Iran) suffered from urinary tract infections during a period of six months. The prevalence of ESBL producing <i>K. pneumoniae</i> and <i>P. aeruginosa</i> was evaluated by disk diffusion test and polymerase chain reaction (PCR) by detecting TEM and CTX-M gene.</p> <p>Results: The results of the study revealed that the prevalence of ESBL producing <i>P. aeruginosa</i> and <i>K. pneumoniae</i> by disk diffusion test was 13.3% for <i>P. aeruginosa</i> and 66.6% for <i>K. pneumoniae</i>. Seventy five percent and 65% of <i>K. pneumoniae</i> harboured the gene TEM and CTX-M, respectively. Forty five percent of <i>P. aeruginosa</i> isolates harboured the gene TEM but none of them demonstrated the gene CTX-M using PCR method.</p> <p>Conclusion: ESBL producing <i>P. aeruginosa</i> and <i>K. pneumoniae</i> isolates showed a high prevalence in this study. Therefore it seems that continuous surveillance is essential to monitor the ESBLs producing microorganisms in hospitals and community.</p> <p>Copyright © 2014 Zahedan University of Medical Sciences. All rights reserved.</p>

Introduction

Development of microbial resistance to antibiotics is a global concern. Isolation of microbial agents less susceptible to regular antibiotics and appearance of increasing resistant isolates during antibacterial therapy is rising throughout the world. *Klebsiella pneumoniae* is an important pathogen that causes urinary tract infections (UTIs), pneumonia, and intra-abdominal infections in hospitalized immunocompromised patients with severe underlying diseases [1]. Resistance of *K. pneumoniae* to many antibiotics such as extended spectrum cephalosporins due to plasmid mediated enzymes (extended spectrum beta-lactamases (ESBLs) results in treatment failure of infections caused by these isolates [2]. *Pseudomonas aeruginosa* can colonize human body sites, with a preference for moist areas, such as the perineum, axilla, ear, nasal mucosa and throat; as well as stools. The prevalence of colonization by *P. aeruginosa* in healthy subjects is usually low, but higher colonization rates can be observed following hospitalization, especially amongst subjects treated with broad-spectrum antimicrobial agents special for extended spectrum cephalosporin.

Colonization is common in the respiratory tract of mechanically ventilated patients, in the gastrointestinal tract of patients receiving anticancer chemotherapy, and on the skin of burn patients. Also, sinks, mops, disinfectant solutions, respiratory equipment, food mixers and other moist environments can act as reservoirs of *P. aeruginosa* in the hospital setting [3, 4]. Therefore, it is important to find out resistance in antimicrobial agents used for this purpose. There is a problem that occurred among ESBL-producing Enterobacteriaceae which have widely caused the spread of infections worldwide [5-7]. Although, today hundreds variant of ESBLs have been described [8, 9], but the most common of them are derivatives of TEM or SHV enzymes. Also, in recent years non-TEM and non-SHV ESBLs have been reported, mainly the CTX-M enzymes [7-11]. The aim of this study was to evaluate the antimicrobial susceptibility of ESBL producing *K. pneumoniae* and *P. aeruginosa* from hospitalized patients with urinary tract infection (UTI) and the distribution of TEM and CTX-M genes among ESBL-producing *K. pneumoniae* and *P. aeruginosa* causing Urinary Tract Infection.

Materials and Methods

Isolation of bacteria: All 180 strains (30 *Klebsiella pneumoniae* and 150 *Pseudomonas aeruginosa*) isolated from urine culture of hospitalized patients (Amir Al-Momenin Hospital, Zabol, south-eastern Iran) suffered from urinary tract infections during the years 2010- 2011 were evaluated. Isolated bacteria were identified by Gram's stain and standard biochemical tests [12].

Phenotypic detection of ESBLs: ESBLs producing strains detected using single or combined ceftazidime-clavulanic acid disks (MAST Co. UK). This was a combination test for phenotypic confirmatory of ESBLs [13, 14]. Phenotypic detection of ESBLs was defined by an increase ≥ 5 mm in the inhibition zone around clavulanic acid disk comparing with zone around the disks of without clavulanic acid. For activity of antibacterial assay, bacterial suspensions with concentration of 1.5×10^8 cfu/ml (0.5 McFarland standard) were prepared in nutrient broth. Oxid combination disk method was used for detection of ESBLs producing organisms. In this method the bacteria were cultured on a Muller-Hinton agar plate, then ampicillin (25 µg), Trimethoprim-Sulfamethoxazol (1.25+23.15), ceftazidime (30 µg), gentamicin (10 µg), nitrofurantoin (30 µg), nalidixic acid (30 µg) and ciprofloxacin (30 µg) disks (Mast, UK) were placed on media in 20-30 mm with other disks. The plates were incubated for 18-24 h at 37°C [15].

DNA extraction, PCR: The colonies of ESBLs producing organisms were suspended in (Tris+ EDTA) TE buffer and their DNA were extracted by simple boiling [16]. The PCR method for detection of TEM and CTX- M gene was performed as described previously with minor modifications [17]. Briefly, blaTEM and blaCTX-M genes were detected using specific pair of primers (Moosavian and Deiham, 2010) (Table 1). The PCR mixture consisted of 10 pmol of each primers, 1 µl DNA sample (3 µg/µl), 1.5 mM MgCl₂, 0.2 mM each dNTP, and 5 U Taq DNA polymerase (Cinagen, Iran) in a total number of 50 µl of PCR reaction. Amplification of TEM gene was performed by following program: initial denaturation at 94°C for 2 min and 35 cycles of 1 min at 94°C, 30 sec at 52°C and 1 min at 72°C. Five min at 72°C was considered for the final extension. Then, PCR products were analyzed by agarose gels electrophoresis.

Statistical Analysis: All the experiments and measurement were repeated at least three times. Descriptive statistical analyses were performed using SPSS and Excel 2010 software.

Results

***Klebsiella pneumoniae*:** Twenty (66.6%) out of 30 *K. pneumoniae* isolates were ESBLs producing organisms by disc diffusion. Antibiotic susceptibility of ESBL producing *K. pneumoniae* was evaluated for 6 antimicrobial. However, overall *K. pneumoniae* were resistance to 6 of the agent including ampicillin (65%), gentamicin (30%), trimethoprim-sulfamethoxazol (25%), ciprofloxacin (20%), nitrofurantoin (15%) and nalidixic acid (15%). As was shown in table 2, the most frequent resistance was observed for ampicillin and the least for ciprofloxacin. The amplification of TEM and CTX- M of *K. pneumoniae* revealed that 15 (75%) and 13 (65%) of the isolates harboured those genes and the rest were negative (Table 4).

***Pseudomonas aeruginosa*:** Twenty (13.3%) out of 150 *P. aeruginosa* isolates were ESBLs producing organisms by disc diffusion. Antibiotic susceptibility of ESBL producing *P. aeruginosa* was evaluated for 6 antimicrobial. However, overall *P. aeruginosa* were resistance to 6 of the agent including ampicillin (85%), trimethoprim-sulfamethoxazol (65%), nitrofurantoin (65%), nalidixic acid (65%), gentamicin (25%), and ciprofloxacin (15%). As was demonstrated in table 3 the most frequent resistance was seen for ampicillin, trimethoprim-sulfamethoxazol, nitrofurantoin and nalidixic acid; and the least for ciprofloxacin. The amplification of TEM and CTX- M of *P. aeruginosa* revealed that 9 (45%) of the isolates harboured the TEM gene and none of them demonstrated the CTX- M gene (Table 5).

Table 1. The oligonucleotide primers used for amplification of Beta - lactamase genes

NO	Primers	Sequences
1	TEM	5' ATAAAATTCTTGAAGACGAAA 3' 5' GACAGTTACCAATGCTTAATCA 3'
2	CTX-M	5' TTAATGATGACTCAGAGCATTC 3' 5' GATACCTCGCTCCATTATTG 3'

Table 2. Percentage of antimicrobial susceptibility of 20 strains of *Klebsiella pneumoniae*

	Am (%)	Fm (%)	NA (%)	CP (%)	SXT (%)	CAZ (%)	Gm (%)
S	0	80	60	70	70	0	20
I	35	60	25	10	5	0	50
R	65	30	15	20	25	100	30

Gm= gentamicin, CAZ= ceftazidime, SXT= sulfamethoxazol-trimethoprim, CP= ciprofloxacin, NA= nalidixic acid, Fm= nitrofurantoin, AM= ampicillin
S= Sensitive, I= Intermediate, R= Resistant

Table 3. Percentage of antimicrobial susceptibility of 20 strains of *Pseudomonas aeruginosa*

	Am (%)	Fm (%)	NA (%)	CP (%)	SXT (%)	CAZ (%)	Gm (%)
S	0	60	10	60	20	0	20
I	15	20	25	25	15	0	55
R	85	20	65	15	65	100	25

Gm= gentamicin, CAZ= ceftazidime, SXT= sulfamethoxazol-trimethoprim, CP= ciprofloxacin, NA= nalidixic acid, Fm= nitrofurantoin, AM= ampicillin
S= Sensitive, I= Intermediate, R= Resistant

Table 4. Frequency of TEM and CTX-M genes in ESBLs-positive *Klebsiella pneumoniae*

	CTX-M gene	TEM gene	Am	Fm	NA	CP	SXT	CAZ	Gm
1	+	+	R	I	S	S	S	R	I
2	+	-	R	I	S	S	S	R	S
3	-	+	I	I	I	S	S	R	S
4	+	+	I	I	R	S	S	R	S
5	+	+	I	I	S	S	S	R	S
6	+	+	R	R	S	S	S	R	I
7	-	-	I	R	S	S	S	R	I
8	+	+	R	I	S	S	S	R	I
9	+	-	R	I	S	S	S	R	I
10	+	+	R	I	S	S	S	R	I
11	-	+	R	I	S	S	S	R	I
12	+	-	R	I	S	S	S	R	I
13	-	+	R	I	R	R	R	R	R
14	+	+	R	S	R	I	R	R	R
15	-	+	I	R	S	S	S	R	I
16	+	+	R	R	S	S	S	R	I
17	+	+	I	I	I	R	R	R	R
18	-	+	R	S	I	R	R	R	R
19	+	+	I	R	I	R	I	R	R
20	-	-	R	R	I	I	R	R	R

Gm= gentamicin, CAZ= ceftazidime, SXT= sulfamethoxazol-trimethoprim, CP= ciprofloxacin, NA= nalidixic acid, Fm= nitrofurantoin, AM= ampicillin
S= Sensitive, I= Intermediate, R= Resistant

Table 5. Frequency of TEM and CTX-M genes in ESBLs-positive *Pseudomonas aeruginosa* isolates

	CTX-M gene	TEM gene	Am	Fm	NA	CP	SXT	CAZ	Gm
1	-	-	R	R	R	S	R	R	S
2	-	+	R	S	S	S	R	R	I
3	-	-	R	S	R	S	R	R	I
4	-	-	R	S	R	I	S	R	I
5	-	-	R	S	I	R	S	R	R
6	-	+	R	S	R	R	I	R	R
7	-	+	R	R	R	S	R	R	S
8	-	-	I	I	I	I	R	R	I
9	-	+	I	S	R	S	S	R	I
10	-	-	R	R	R	S	R	R	I
11	-	+	R	S	I	I	R	R	R
12	-	-	R	R	R	S	R	R	I
13	-	+	R	S	R	S	R	R	R
14	-	-	R	S	S	R	S	R	I
15	-	-	R	I	I	I	I	R	I
16	-	+	I	I	I	I	S	R	R
17	-	-	R	S	R	S	R	R	S
18	-	+	R	S	R	S	R	R	I
19	-	+	R	S	R	S	R	R	I
20	-	-	R	I	R	S	R	R	S

Gm= gentamicin, CAZ= ceftazidime, SXT= sulfamethoxazol-trimethoprim, CP= ciprofloxacin, NA= nalidixic acid, Fm= nitrofurantoin, AM= ampicillin
S= Sensitive, I= Intermediate, R= Resistant




Figure 1. PCR results for TEM and CTX-M genes. Lane numbers 1-6 shows the fragment of CTX-M, lane 7 demonstrates the 50 bp DNA size marker and 8-11 shows the fragment of TEM gene

Discussion

Based on the results of this study, the prevalence of ESBL producing *P. aeruginosa* and *K. pneumoniae* by disk diffusion test was high, 13.3% for *P. aeruginosa* and 66.6% for *K. pneumoniae*. 75% and 65% of *K. pneumoniae* isolates harboured the gene TEM and CTX-M, respectively and 45% of isolated *P. aeruginosa* harboured the gene TEM by PCR method. Resistance to beta-lactam antibiotics of Gram- negative bacteria isolated from clinical samples has been increased worldwide. Based on the results of this study, the prevalence of ESBL producing *P. aeruginosa* and *K. pneumoniae* by disk diffusion test was high, 13.3% for *P. aeruginosa* and 66.6% for *K. pneumoniae*. 75% and 65% of *K. pneumoniae*

isolates harboured the gene TEM and CTX-M, respectively and 45% of isolated *P. aeruginosa* harboured the gene TEM by PCR method. The prevalence of the ESBL producing organisms in Taiwan was in the range of 8.5% to 29.8% in *K. pneumoniae* and 1.5% to 16.7% in *E. coli* [18]. In Isfahan, 51% of isolated *E. coli* and 70% of isolated *K. pneumoniae* were ESBLs producing bacteria [19]. The prevalence of the ESBL producing organisms in Tehran were, 21% for *E. coli* and 12% for *K. pneumoniae* [20]. Feizabadi showed that 72% of *K. pneumoniae* strains isolated from Tehran hospitals were ESBLs-producing [21]. Other studies demonstrated the prevalence of 57.1 and 55%, for ESBL-producing *K. pneumoniae*, respectively based on phenotypic confirmatory test [6, 22]. In another study in Mashhad, the prevalence of ESBLs producing *E. coli* and *K. pneumoniae* was reported 57.5% and 61% and generally the prevalence of ESBLs producing organisms were 59.2% by Kirby-Baure disk diffusion method and the phenotypic disk confirmatory test [23]. In another study, by disk diffusion test, resistance of *K. pneumoniae* to ceftazidime and cefotaxime were 34.7% and 33.5% respectively. The prevalence of blaSHV, blaCTX-M, blaTEM among these isolates were 26%, 24.5%, 18%, respectively [24].

A report from Tehran revealed that 69.7% of *K. pneumoniae* isolated from Tehran were ESBL positive

and the prevalence of blaTEM, blaSHV, blaCTX-M-I and blaCTX-M-III among these isolates was 54%, 67.4%, 46.51% and 29%, respectively [25]. In another study from Tehran, the prevalence of blaSHV and blaTEM genes for *K. pneumoniae* was reported 67% and 16%, respectively [26].

In summary, the prevalence of ESBLs producing organisms in Zabol is high and most *K. pneumoniae* and *P. aeruginosa* isolates harboured CTX and TEM genes. It seems necessary for clinicians and health care systems to be fully aware of ESBLs producing microorganisms. The ESBLs production monitoring is recommended to avoid treatment failure and suitable infection control in Iran.

Acknowledgements

This study was supported by Institute of Plant Biotechnology University of Zabol, Zabol, Iran.

Authors' Contributions

All authors had equal role in design, work, statistical analysis and manuscript writing.

Conflict of Interest

The authors declare no conflict of interest.

Funding/Support

Institute of Plant Biotechnology, University of Zabol.

References

- Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: Epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998; 11(4): 589-603.
- Iroha IR, Egbu OA, Ngozi AT, et al. Extended spectrum beta-lactamase (ESBL) mediated resistance to antibiotics among Klebsiella pneumoniae in enugu Metropolis. Maced J Med Sci 2009; 2(3): 196-199.
- Morrison AJ Jr, Wenzel RP. Epidemiology of infections due to Pseudomonas aeruginosa. Rev Infect Dis 1984; 6 Suppl 3: S627-S642.
- Pollack M. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000: 2310-2335.
- Quinteros M, Radice M, Gardella N, et al. Extended-Spectrum β -Lactamases in Enterobacteriaceae in Buenos Aires, Argentina, Public Hospitals. Antimicrob Agents Chemother 2003; 47(9): 2864-2867.
- Al-Agamy MH, Shibl AM, Tawfik AF. Prevalence and molecular characterization of extended-spectrum β -lactamase-producing Klebsiella pneumoniae in Riyadh, Saudi Arabia. Ann Saudi Med 2009; 29(4): 253-257.
- Apisarnthanarak A, Kiratisin P, Mundy LM. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum β -lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2008; 29(7): 671-674.
- Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352(4): 380-91.
- Rawat D, Nair D. Extended-spectrum β -lactamase in gram negative bacteria. J Glob Infect Dis 2010; 2(3): 263-274.
- Mohamudha PR, Srinivas AN, Rahul D, et al. Molecular epidemiology of Multidrug resistant Extended-Spectrum β -Lactamase Producing Klebsiella pneumoniae outbreak in a neonatal intensive care unit. Int J Collab Res Intern Med Public Health (IJCRIMPH) 2010; 2(7): 226-238.
- Munier GK, Johnson CL, Snyder JW, et al. Positive extended-spectrum- β -lactamase (ESBL) screening results may be due to AmpC β -lactamases more often than to ESBLs. J Clin Microbiol 2010; 48(2): 673-674.
- Forbes BA, Sahm DF, Weissfeld AS. Bailey & Scott's diagnostic microbiology. 12th ed. Missouri: Mosby Co; 2007: 323-333.
- Thomson KS, Sanders CC. Detection of extended-spectrum β -lactamases in members of the family Enterobacteriaceae: Comparison of the double-disk and three-dimensional tests. Antimicrob Agents Chemother 1992; 36(9): 1877-1882.
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility testing. 11th ed. Approved Standard M100-S17. USA: Wayne, Pa.; 2007.
- Well B, Stood RJ. The genus Shigella. In: Krieg NR, Holt JG, editors. Bergy's manual of systemic bacteriology. 8th ed. Hong Kong: Wilkins; 1989: 423-427.
- Varaiya AY, Dogra JD, Kulkarni MH and Bhalekar PN. Extended spectrum beta lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae in diabetic foot infection. Indian J Pathol Microbiol 2008; 51(3): 370-2.
- Shahcheragh IF, Nasiri S, Noveiri H. The survey of genes encoding beta-lactamases, in Escherichia coli resistant to beta-lactam and non-beta-lactam antibiotics. Iran J Basic Med Sci 2010; 13(1): 230-237.
- Yu WL, Chuang YC, Walther-Rasmussen J. Extendedspectrum β -lactamases in Taiwan: epidemiology,

- detection, treatment and infection control. *J Microbiol Immunol Infect* 2006; 39(4): 264-277.
19. Masjedian-Jazi F, Valehi F, Talebi A, et al. [Molecular characterization of resistance to extended-spectrum antibiotics in *Escherichia coli* and *Klebsiella pneumoniae*] Persian. *Iran J Med Microbiol* 2007; 2: 27-34.
20. Behroozi A, Rahbar M, Yousefi J. Frequency of extended spectrum beta-lactamase (ESBLs) producing *Escherichia coli* and *Klebsiella pneumoniae* isolated from urine in an Iranian 1000-bed tertiary care hospital. *Afr J Microbiol Res* 2010; 4(9): 881-884.
21. Feizabadi MM, Mohammadi-Yeganeh S, Mirsalehian A, et al. Genetic characterization of ESBL-producing strains of *Klebsiella pneumoniae* from Tehran hospitals. *J Infect Dev Ctries* 2010; 4(10): 609-615.
22. Tasli H, Bahar IH. Molecular characterization of TEM and SHV derived ESBL In hospital based Enterobacteriaceae in Turkey. *Jpn J Infect Dis* 2005; 58(3): 162-167.
23. Bazzaz BS, Naderinasab M, Mohamadpoor AH, et al. The prevalence of extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* among clinical isolates from a general hospital in Iran. *Acta Microbiol Immunol Hung* 2009; 56(1): 89-99.
24. Nasehi L, Shahcheraghi F, Nikbi VS and Nematzadeh S. PER, CTX-M, TEM and SHV Beta-lactamases in clinical Isolates of *Klebsiella pneumoniae* isolated from Tehran, Iran. *Iran J Basic Med Sci* 2010; 13(3): 111-118.
25. Feizabadi MM, Delfani S, Raji N, et al. Distribution of bla (TEM), bla (SHV), bla (CTX-M) genes among clinical isolates of *Klebsiella pneumoniae* at Labbafinejad hospital, Tehran, Iran. *Microb Drug Resist* 2010; 16(1): 49-53.
26. Paterson DL, Hujer KM, Hujer AM, et al. Extended-spectrum betalactamases in *Klebsiella pneumoniae* bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases international *Klebsiella* study group. *Antimicrob Agents Chemother* 2003; 47(11): 3554-3560.

Please cite this article as: Saeidi S, Alavi-Naini R, Shayan S. Antimicrobial susceptibility and distribution of TEM and CTX-M genes among ESBL-producing *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* causing urinary tract infection. *Zahedan J Res Med Sci (ZJRMS)* 2014; 16(4): 1-5.